Menu Search
Equities

M3 Inc

2413:TYO

M3 Inc

Actions
Health CareHealth Care Providers
  • Price (JPY)1,495.00
  • Today's Change4.00 / 0.27%
  • Shares traded3.56m
  • 1 Year change-36.57%
  • Beta1.2507
Data delayed at least 15 minutes, as of Dec 03 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 29-Nov-24
Select bar for recommendation details.
Recommendations29-Nov-24
Buy1
Outperform4
Hold9
Sell1
Strong Sell0

Share price forecast in JPY

The 13 analysts offering 12 month price targets for M3 Inc have a median target of 1,650.00, with a high estimate of 3,300.00 and a low estimate of 1,120.00. The median estimate represents a 10.37% increase from the last price of 1,495.00.
High120.7%3,300.00
Med10.4%1,650.00
Low-25.1%1,120.00

Dividends in JPY

In 2024, M3 Inc reported a dividend of 21.00 JPY, which represents a 10.53% increase over last year. The 11 analysts covering the company expect dividends of 20.37 JPY for the upcoming fiscal year, a decrease of 2.99%.
Div growth (TTM)10.53%
More ▼

Earnings history & estimates in JPY

On Oct 30, 2024, M3 Inc reported 2nd quarter 2025 earnings of 8.91 per share.
The next earnings announcement is expected on Jan 29, 2025.
Average growth rate-7.65%
M3 Inc reported annual 2024 earnings of 66.68 per share on Apr 26, 2024.
Average growth rate+28.16%
More ▼

Revenue history & estimates in JPY

M3, Inc. had 2nd quarter 2025 revenues of 60.61m. This missed the 64.13m consensus estimate of the 8 analysts following the company. This was 5.60% above the prior year's 2nd quarter results.
Average growth rate+1.17%
M3, Inc. had revenues for the full year 2024 of 238.88m. This was 3.49% above the prior year's results.
Average growth rate+16.65%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.